April N Naegeli - JoVE Visualize

Showing results (41-50 of 45) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 45 results.

Open Forum Infectious Diseases|May 2, 2022

Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 TrialPeter Chen, Gerhard Behre, Corey Hebert, et al.

Crohn'S & Colitis 360|February 13, 2023

Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas' Inflammatory Bowel Disease RegistryRaymond K Cross, April N Naegeli, Ryan W Harrison, et al.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 20, 2020

Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.

Crohn'S & Colitis 360|February 13, 2023

Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative ColitisMarla C Dubinsky, Remo Panaccione, James D Lewis, et al.

Gastroenterology|November 8, 2021

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's DiseaseBruce E Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, et al.

Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 45 results.

Open Forum Infectious Diseases|May 2, 2022

Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 TrialPeter Chen, Gerhard Behre, Corey Hebert, et al.

Crohn'S & Colitis 360|February 13, 2023

Disease Burden and Patient-Reported Outcomes Among Ulcerative Colitis Patients According to Therapy at Enrollment Into CorEvitas' Inflammatory Bowel Disease RegistryRaymond K Cross, April N Naegeli, Ryan W Harrison, et al.

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 20, 2020

Efficacy and Safety of Continued Treatment With Mirikizumab in a Phase 2 Trial of Patients With Ulcerative ColitisWilliam J Sandborn, Marc Ferrante, Bal R Bhandari, et al.

Crohn'S & Colitis 360|February 13, 2023

Impact of Bowel Urgency on Quality of Life and Clinical Outcomes in Patients With Ulcerative ColitisMarla C Dubinsky, Remo Panaccione, James D Lewis, et al.

Gastroenterology|November 8, 2021

Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn's DiseaseBruce E Sands, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, et al.

Pageof 5